Sampo has filed an application to extend the Group's Partial Internal Model
Sampo has filed an application to extend the Group's Partial Internal Model
Advertisement
Following the legal merger of If and Topdanmark on 1 July 2025, Sampo has filed an application to the Swedish FSA (Finansinspektionen) to extend the Group's Partial Internal Model to include the operations formerly under Topdanmark. Sampo expects that the application process will be completed in late 2025 or early 2026 at the latest.
Sampo estimates that the extended model could reduce the group-level solvency capital requirement by around EUR 60-90 million.
SAMPO PLC
Investor Relations and Group Communications
For further information, please contact:
Sami Taipalus
Head of Investor Relations
tel. +358 10 516 0030
Distribution:
Nasdaq Helsinki
Nasdaq Stockholm
Nasdaq Copenhagen
London Stock Exchange
FIN-FSA
The principal media
www.sampo.com
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
16 hours ago
- Business Upturn
Newcastle pushing to get Anthony Elanga's deal done
Newcastle United are actively in the market for Nottingham Forest's Anthony Elanga who was phenomenal in the last season for the club. By Ravi Kumar Jha Published on July 4, 2025, 08:33 IST Newcastle United are actively in the market for Nottingham Forest's Anthony Elanga who was phenomenal in the last season for the club. His superb goals and assists helped Nottingham book their place in the European competition. They are going to play either Europa League or Europa Conference League next season. Newcastle have also reportedly bid €55 million for the forward as they want to get it done soon. Newcastle United are making moves in the summer transfer window and have set their sights on Nottingham Forest winger Anthony Elanga, who enjoyed a breakout season in 2024/25. The Swedish international was instrumental in Forest's impressive campaign, contributing crucial goals and assists that helped the club secure a spot in European competition for the upcoming season — either in the UEFA Europa League or Europa Conference League. Elanga's pace, directness, and end product caught the attention of several top clubs, but it's Newcastle who appear to be leading the race. The Magpies have reportedly tabled a €55 million bid for the 22-year-old, aiming to finalize the deal swiftly as they look to strengthen their attack ahead of a demanding campaign. With Newcastle looking to return to European competition themselves, Eddie Howe sees Elanga as a dynamic addition who can offer width, creativity, and a goal threat from wide areas. The move, if successful, would mark a significant investment in one of the Premier League's rising stars. Ahmedabad Plane Crash Ravi kumar jha is an undergraduate student in Bachelor of Arts in Multimedia and Mass Communication. A media enthusiast who has a strong hold on communication and he also has a genuine interest in sports. Ravi is currently working as a journalist at
Business Wire
a day ago
- Business Wire
GenSight Biologics Announces the Closing of the Company's c. €4 Million Private Placement
PARIS--(BUSINESS WIRE)--Regulatory News: NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH AFRICA GenSight Biologics (the " Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the closing of its EUR 3,908,715.39 private placement (the ' Private Placement '). The Private Placement resulted in the issuance of 21,251,267 ordinary shares of the Company (the " Offered Shares"). The Offered Shares will be admitted to trading on Euronext Paris on July 3, 2025 (ISIN FR0013183985/SIGHT). The issuance of: The 1,850,000 pre-funded warrants (the " Offered Pre-Funded Warrants") giving the right to subscribe to 1,850,000 additional ordinary shares (the " Pre-Funded Warrant Shares"); and The 23,101,267 warrants (the " Offered Investor Warrants") giving the right to subscribe to 23,101,267 additional ordinary shares (the " Investor Warrant Shares") is expected to take place tomorrow, July 4, 2025. The Offered Investor Warrants will be admitted to trading on the Euronext Growth market in Paris (" Euronext Growth Paris") on July 7, 2025 (ISIN FR0014010IB4/SIGBS). The Offered Pre-Funded Warrants will not be admitted to trading on any venue. Part of the proceeds, EUR 0.7 million, has been used for the repayment in principal on the convertible bonds held by Heights Capital through offset against their subscription. Maxim Group, LLC acted as sole placement agent for the Private Placement in the United States, pursuant to an agreement entered into with the Company. Risk factors The Company draws the attention of the public to the risk factors relating to the Company and its business described in its 2024 Universal Registration Document, as amended by the Information Document published by the Company on July 1 st, 2025, both of which are available free of charge on the Company's website ( . About GenSight Biologics S.A. GenSight Biologics S.A. is a clinical-stage biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight Biologics' pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. GenSight Biologics' lead product candidate, GS010 (lenadogene nolparvovec) is in Phase III in Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible blindness in teens and young adults. Using its gene therapy-based approach, GenSight Biologics' product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery. Disclaimer Not for release, directly or indirectly, in or into the United States of America, Canada, Australia, Japan or South Africa. This press release and the information contained herein do not contain or constitute an offer to subscribe or purchase, or the solicitation of an order to purchase or subscribe, for securities in the United States of America or in any other jurisdiction where such an offer or solicitation would be unlawful. The securities referred to herein have not been and will not be registered under the Securities Act, or under the securities laws of any state or other jurisdiction of the United States of America, and may not be offered or sold in the United States of America except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with the securities laws of any state or any other jurisdiction of the United States. GenSight does not intend to make a public offering of the securities in the United States of America. The distribution of this press release may be subject to legal or regulatory restrictions in certain countries. Persons in possession of this press release should inform themselves of and observe any local restrictions. The information contained herein is subject to change without notice. Forward-Looking Statements This press release contains forward-looking statements. All statements, other than statements of historical facts, included in this press release are forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the completion expected proceeds and anticipated use of proceeds of the Private Placement; the anticipated cash runway of the Company; and future expectations, plans and prospects of the Company. Words such as 'anticipates,' 'believes,' 'expects,' 'intends,' 'projects,' and 'future' or similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions and no assurance can be given that the proposed securities offering discussed above will be consummated on the terms described or at all. Completion of the proposed Private Placement and the terms thereof are subject to numerous factors, many of which are beyond the control of the Company, including, without limitation, market conditions, failure of customary closing conditions and the risk factors and other matters set forth in the filings the Company makes with the AMF from time to time. The Company expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as may be required by law.
Business Wire
a day ago
- Business Wire
voxeljet AG - Court confirms StaRUG Plan
FRIEDBERG, Germany--(BUSINESS WIRE)--voxeljet AG (the 'Company', 'voxeljet', or 'we'), a provider of high-speed, large-format 3D printers and on-demand parts services to industrial and commercial customers, today announced that main investor Anzu Special Acquisition Corp II ('Anzu') will contribute new equity capital of EUR 2.5 million as part of a plan confirmed today by the court in Munich. The plan additionally provides for a debt waiver totalling EUR 3.5 million debt owed to Anzu and extension of the debt maturity until 2031. These measures are intended to ensure the Company's long-term financing and position voxeljet for future success. CEO Rudolf Franz comments: 'We implemented the necessary process in a short period of time to minimize disruption to our operating business. With the court's confirmation of the plan, we believe this phase of the process is complete.' Franz added: 'This plan provides continuity of our operations, reinforcing our commitment to reliably serving our customers and meeting their ongoing and future needs. The plan will secure sustainable financial stability and can lead voxeljet into a successful future.' The court confirmed the plan in accordance with the German Corporate Stabilization and Restructuring Act (StaRUG) ('StaRUG Plan'). As previously communicated, the plan provides for a simplified reduction of the share capital of voxeljet AG to zero euros. The court-confirmed plan will result in the exclusion of the current shareholders of voxeljet AG without compensation. Subsequently, the company's capital will be increased excluding the subscription rights of the current shareholders. Anzu, as the only financial creditor affected by the plan, will exclusively be admitted to subscribing to the new shares. The debt waiver will be composed of EUR 500,000 to be waived in 2025 and EUR 1,500,000 in each of 2026 and 2027. Furthermore, the annual interest rate will be reduced to 3% p.a. from July 2026 onwards. No interest payments are due until after June 30, 2026. The plan also stipulates that the promissory note loans will only become due for repayment on January 2, 2031. The plan shall be implemented immediately after the plan confirmation becomes legally binding. ABOUT VOXELJET voxeljet was founded in 1999 as a spin-off from Technical University Munich (TUM) with a clear vision in mind: to establish a new manufacturing standard by developing new generative processes for the series-production of complex components using 3D printing. Voxeljet is a globally acting, leading provider of high-speed, large-format 3D printers and on-demand 3D printed parts to industrial and commercial customers. Components manufactured with the help of voxeljet technology are flying in space, make mobility more efficient and enable the production of new engineering solutions. Visit voxeljet's website and follow us on LinkedIn. ABOUT ANZU PARTNERS Anzu Partners is an investment firm that focuses on clean tech, industrial and life science technology companies with the potential to transform their industries. Anzu works with entrepreneurs to develop and commercialize technological innovations by providing capital alongside deep expertise in business development, market positioning, global connectivity, and operations. As of 2024, Anzu Partners managed assets of approximately $1 billion with a team of over fifty professionals in offices across Atlanta, Boston, San Diego, Tampa, and Washington DC. For more information, please visit
